MASLD/Metabolic Associated Steatotic Liver Disease. Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: Intervention group: Patients who will be randomly administered with empagliflozin 10 mg once daily orally for six months without modifying existing treatment for MASLD. Intervention 2:
Sponsors
King Edward Medical University
Eligibility
Sex/Gender
All
Age
30 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients having age between 30-65 years Both male and female Patients having -MASLD receiving Empagliflozin therapy after giving consent, along with standard therapy
Exclusion criteria
Exclusion criteria: Patients having HCV, HBV, those having tumor of liver Patients that are unable to understand local languages Non cooperative patients Critical cases (ICU admitted, mechanical ventilation, coma patient, GCS score less than 10)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in liver fibrosis as measured by the FIB-4 Index. Timepoint: After completion of 6 months of treatment. Method of measurement: Pre- and post-intervention FIB-4 scores were used to assess the efficacy of empagliflozin. | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety and health-related quality of life as measured by the SF-36 Health Survey. Timepoint: After completion of 6 months of treatment. Method of measurement: SF-36 was used to assess both physical and mental health status of participants. | — |
Countries
Pakistan
Contacts
Public ContactDr. Muhammad Umer Sheikh
King Edward Medical University
Outcome results
None listed